KospicyKorean filings in English
Filings / CJ Bioscience

Acquisition of Shares in Another Company

CJ Bioscience · 타법인주식및출자증권취득결정

8-KKOSDAQ · 311690 Filed 2026-11-10Korean original on DART

English form view 55% translated

Translated from a fixed dictionaryLeft in Korean (free text, names)Numbers and dates are copied unchanged

Decision to acquire shares and equity securities of another company

1. IssuerCompany name (nationality)EzBiome, Inc.(미국)CEO한호윤
Capital (KRW)3,374,591,956Relationship to CompanySubsidiary
Total Shares Issued (shares)99,444Principal business유전체 분석 등 (연구 및 개발업)
-New shares acquired via 3-party allotment within last 6 monthsNo
2. Acquisition DetailsShares acquired (shares)185,667
Acquisition Amount (KRW)7,551,262,557
Equity (KRW)53,639,266,970
% of Equity14.1
Large EnterpriseN/A
3. Shares Held and Ownership Ratio After AcquisitionShares Owned (shares)285,111
Ownership (%)100
4. Acquisition Method주주배정 유상증자 참여(현금취득)
5. Purpose of Acquisition종속회사의 차입금 상환 및 청산
6. Planned Acquisition Date2026-11-23
7. Subject to material event report on asset acquisitionNo
-Total assets at latest fiscal year-end (KRW)72,337,467,194Acquisition price / total assets (%)10.4
8. Backdoor ListingNo
-Plans for third-party allotment capital increase etc. within 6 months (3)No
9. Issuer (other company) meets backdoor listing criteriaNo
10. Board Resolution Date (Decision Date)2026-11-10
- Outside Directors PresentPresent (persons)3
Absent (persons)0
- Auditor (Audit Committee Member) AttendancePresent
11. Subject to KFTC FilingN/A
12. Put Option Agreements, etc.No
- Contract Details-
13. Other Matters Relevant to Investment Decisions- 본 건은 당사가 지분 100% 보유한 종속회사인 EzBiome, Inc.(미국)이 기존 차입금을 상환하고 후속 청산절차를 추진하기 위해 실시하는 유상증자에 당사가 출자를 결정한 건입니다. - 본 건은 유상증자에 의한 신주 취득으로 원시취득에 해당하여 자본시장법상 '주요사항보고서' 제출 대상에 해당하지 않습니다. - 상기 ‘2. 취득내역’의 취득금액은 미화 $5,570,010으로 2026-11-10 서울외국환중개 고시 매매기준율 (1,355.70KRW/USD)을 적용하여 작성되었고, 환율에 따라 변동될 수 있습니다. - 상기 '2. 자기자본' 및 상기 '7. 최근 사업연도말 자산총액(원)' 당사의 '25년말 연결 재무제표 기준입니다. - 6. 취득예정일자'는 주금 납입 예정일입니다. - 10. 이사회결의일(결정일)'은 당사의 이사회결의일입니다. - 상기 공시내용은 향후 진행상황에 따라 변동이 있을 수 있으며, 변동이 있을 경우 재공시 예정입니다. - 하기 [발행회사의 요약 재무상황]은 당해연도(2025년), 전년도(2024년), 전전년도(2023년) 기준이며 [상대방에 관한 사항]은 '25년말 연결재무제표 기준입니다.

[Issuer's Summary Financial Position]

(Unit: KRW m)

CategoryTotal AssetsTotal LiabilitiesTotal EquityPaid-in CapitalRevenueNet Income
Current year6007,449-6,8493,375321-1,161
Prior Year1,6457,462-5,8173,375300-2,221
Two Years Prior1,8794,882-3,0033,375405-2,015

[Counterparty Information]

1. Personal Information
- General Information
Name (Entity Name)NationalityAddress (Head Office) [Town/District Level Only]Date of Birth (Business Registration No., etc.)
EzBiome, Inc.United StatesEnglewood Cliffs, NJ, USA27-1839212
Occupation (business)유전체 분석 등(연구 및 개발업)
- Largest Shareholder, CEO, Representative Executive Officer and Financial Condition (if counterparty is a corporation)
CategoryNameNumber of SharesOwnership (%)
Largest ShareholderCJ 바이오사이언스(주)99,444100
CEO한호윤--
(Unit: KRW m)
Relevant fiscal year2025Fiscal year-end12
Total Assets600Paid-in Capital3,375
Total Liabilities7,449Revenue321
Total Equity-6,849Net income (loss)-1,161
External Auditor-Business suspendedNo
Audit Opinion-Business closedNo
2. Relationship with Counterparty
1. Relationship between Company and CounterpartySubsidiary
2. Relationship between Company's Largest Shareholder/Officers and CounterpartyNameRelationship with Counterparty
---
3. Transactions in Past 3 Years (excl. Ordinary Transactions)
CategoryTransaction Details
Current year-
Prior Year-
Two Years Prior-